F. Bertucci, P. Finetti, N. Cervera, B. Esterni, F. Hermitte et al., How basal are triple-negative breast cancers?, International Journal of Cancer, vol.9, issue.1, pp.236-240, 2008.
DOI : 10.1002/ijc.23518

E. Rakha, S. Elsheikh, M. Aleskandarany, H. Habashi, A. Green et al., Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes, Clinical Cancer Research, vol.15, issue.7, pp.2302-2310, 2009.
DOI : 10.1158/1078-0432.CCR-08-2132

T. Nielsen, F. Hsu, K. Jensen, M. Cheang, G. Karaca et al., Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma, Clinical Cancer Research, vol.10, issue.16, pp.5367-5374, 2004.
DOI : 10.1158/1078-0432.CCR-04-0220

C. Liedtke, C. Mazouni, K. Hess, F. Andre, A. Tordai et al., Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer, Journal of Clinical Oncology, vol.26, issue.8, pp.1275-1281, 2008.
DOI : 10.1200/JCO.2007.14.4147

D. Silver, A. Richardson, A. Eklund, Z. Wang, Z. Szallasi et al., Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer, Journal of Clinical Oncology, vol.28, issue.7, pp.1145-1153, 2010.
DOI : 10.1200/JCO.2009.22.4725

L. Carey, Directed Therapy of Subtypes of Triple-Negative Breast Cancer, The Oncologist, vol.16, issue.Supplement 1, pp.71-78, 2011.
DOI : 10.1634/theoncologist.2011-S1-71

W. Foulkes, I. Smith, and J. Reis-filho, Triple-Negative Breast Cancer, New England Journal of Medicine, vol.363, issue.20, pp.1938-1948, 2010.
DOI : 10.1056/NEJMra1001389

W. Foulkes, I. Stefansson, P. Chappuis, L. Begin, J. Goffin et al., Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer, CancerSpectrum Knowledge Environment, vol.95, issue.19, pp.1482-1485, 2003.
DOI : 10.1093/jnci/djg050

M. Higgins and J. Baselga, Targeted therapies for breast cancer, Journal of Clinical Investigation, vol.121, issue.10, pp.3797-3803, 2011.
DOI : 10.1172/JCI57152

W. Irvin, J. Carey, and L. , What is triple-negative breast cancer?, European Journal of Cancer, vol.44, issue.18, pp.2799-2805, 2008.
DOI : 10.1016/j.ejca.2008.09.034

N. Turner, A. Tutt, and A. Ashworth, Opinion: Hallmarks of 'BRCAness' in sporadic cancers, Nature Reviews Cancer, vol.56, issue.10, pp.814-819, 2004.
DOI : 10.1093/jnci/90.15.1138

J. Schlessinger, Cell Signaling by Receptor Tyrosine Kinases, Cell, vol.103, issue.2, pp.211-225, 2000.
DOI : 10.1016/S0092-8674(00)00114-8

URL : https://doi.org/10.1016/s0092-8674(00)00114-8

R. Nicholson, J. Gee, and M. Harper, EGFR and cancer prognosis, European Journal of Cancer, vol.37, issue.4, pp.9-15, 2001.
DOI : 10.1016/S0959-8049(01)00231-3

M. Rimawi, P. Shetty, H. Weiss, R. Schiff, C. Osborne et al., Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes, Cancer, vol.350, issue.5, pp.1234-1242, 2010.
DOI : 10.1002/cncr.24816

F. Ciardiello and G. Tortora, A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor, Clin Cancer Res, vol.7, pp.2958-2970, 2001.

E. Van-cutsem, C. Kohne, I. Lang, G. Folprecht, M. Nowacki et al., Mutation Status, Journal of Clinical Oncology, vol.29, issue.15, pp.2011-2019, 2011.
DOI : 10.1200/JCO.2010.33.5091

J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes et al., Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study, Journal of Clinical Oncology, vol.28, issue.31, pp.4697-4705, 2010.
DOI : 10.1200/JCO.2009.27.4860

M. Fukuoka, Y. Wu, S. Thongprasert, P. Sunpaweravong, S. Leong et al., Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non???Small-Cell Lung Cancer in Asia (IPASS), Journal of Clinical Oncology, vol.29, issue.21, pp.2866-2874, 2011.
DOI : 10.1200/JCO.2010.33.4235

J. Baselga, J. Albanell, A. Ruiz, A. Lluch, P. Gascon et al., Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer, Journal of Clinical Oncology, vol.23, issue.23, pp.5323-5333, 2005.
DOI : 10.1200/JCO.2005.08.326

L. Carey, H. Rugo, P. Marcom, E. Mayer, F. Esteva et al., TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer, Journal of Clinical Oncology, vol.30, issue.21, pp.2615-2623, 2012.
DOI : 10.1200/JCO.2010.34.5579

B. Corkery, J. Crown, M. Clynes, O. Donovan, and N. , Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer, Annals of Oncology, vol.20, issue.5, pp.862-867, 2009.
DOI : 10.1093/annonc/mdn710

J. Baselga, P. Gomez, R. Greil, S. Braga, M. Climent et al., Randomized Phase II Study of the Anti???Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer, Journal of Clinical Oncology, vol.31, issue.20, pp.2586-2592, 2013.
DOI : 10.1200/JCO.2012.46.2408

J. Nabholtz, C. Abrial, M. Mouret-reynier, M. Dauplat, B. Weber et al., Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact, Annals of Oncology, vol.25, issue.8
DOI : 10.1093/annonc/mdu183

J. Nabholtz, M. Mouret-reynier, I. Van-praagh, V. Servent, J. Jacquin et al., Cetuximab in combination with docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicentre neoadjuvant pilot phase II study, ASCO Meeting Abstracts, vol.31, p.1057, 2013.

S. Huang, E. Armstrong, S. Benavente, P. Chinnaiyan, and P. Harari, Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR), Cancer Research, vol.64, issue.15, pp.5355-5362, 2004.
DOI : 10.1158/0008-5472.CAN-04-0562

P. Matar, F. Rojo, R. Cassia, G. Moreno-bueno, D. Cosimo et al., Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority Over Single-Agent Receptor Targeting, Clinical Cancer Research, vol.10, issue.19, pp.6487-6501, 2004.
DOI : 10.1158/1078-0432.CCR-04-0870

D. Ferraro, N. Gaborit, R. Maron, H. Cohen-dvashi, Z. Porat et al., Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR, Proceedings of the National Academy of Sciences, vol.311, issue.1-2, pp.1815-1820, 2013.
DOI : 10.1016/j.jim.2006.01.018

R. Jorissen, F. Walker, N. Pouliot, T. Garrett, C. Ward et al., Epidermal growth factor receptor: mechanisms of activation and signalling, Experimental Cell Research, vol.284, issue.1, pp.31-53, 2003.
DOI : 10.1016/S0014-4827(02)00098-8

D. Mckillop, E. Partridge, J. Kemp, M. Spence, J. Kendrew et al., Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, Molecular Cancer Therapeutics, vol.4, issue.4, pp.641-649, 2005.
DOI : 10.1158/1535-7163.MCT-04-0329

M. Scheffler, D. Gion, P. Doroshyenko, O. Wolf, J. Fuhr et al., Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors, Clinical Pharmacokinetics, vol.10, issue.14, pp.371-403, 2011.
DOI : 10.1158/1078-0432.CCR-04-0058

A. Hollestelle, F. Elstrodt, J. Nagel, W. Kallemeijn, and M. Schutte, Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines, Molecular Cancer Research, vol.5, issue.2, pp.195-201, 2007.
DOI : 10.1158/1541-7786.MCR-06-0263

M. Kris, R. Natale, R. Herbst, T. Lynch, J. Prager et al., Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non???Small Cell Lung Cancer, JAMA, vol.290, issue.16, pp.2149-2158, 2003.
DOI : 10.1001/jama.290.16.2149

M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa et al., Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.21, issue.12, pp.2237-2246, 2003.
DOI : 10.1200/JCO.2003.10.038

D. Raben, B. Helfrich, D. Chan, F. Ciardiello, L. Zhao et al., The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer, Clin Cancer Res, vol.11, pp.795-805, 2005.

L. Saltz, N. Meropol, P. Loehrer, . Sr, M. Needle et al., Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, Journal of Clinical Oncology, vol.22, issue.7, pp.1201-1208, 2004.
DOI : 10.1200/JCO.2004.10.182

J. Hecht, A. Patnaik, J. Berlin, A. Venook, I. Malik et al., Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer, Cancer, vol.66, issue.5, pp.980-988, 2007.
DOI : 10.1200/JCO.2005.02.0172

K. Chung, J. Shia, N. Kemeny, M. Shah, G. Schwartz et al., Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry, Journal of Clinical Oncology, vol.23, issue.9, pp.1803-1810, 2005.
DOI : 10.1200/JCO.2005.08.037

X. Wu, M. Rubin, Z. Fan, T. Deblasio, T. Soos et al., Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody, Oncogene, vol.12, pp.1397-1403, 1996.

X. Wu, Z. Fan, H. Masui, N. Rosen, and J. Mendelsohn, Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin., Journal of Clinical Investigation, vol.95, issue.4, pp.1897-1905, 1995.
DOI : 10.1172/JCI117871

C. Kari, T. Chan, M. Rocha-de-quadros, and U. Rodeck, Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage, Cancer Res, vol.63, pp.1-5, 2003.

A. Lin, N. Buckley, A. Lu, N. Kouzminova, and S. Salpeter, Effect of KRAS Mutational Status in Advanced Colorectal Cancer on the Outcomes of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: A Systematic Review and Meta-analysis, Clinical Colorectal Cancer, vol.10, issue.1, pp.63-69, 2011.
DOI : 10.3816/CCC.2011.n.009

S. Benvenuti, A. Sartore-bianchi, D. Nicolantonio, F. Zanon, C. Moroni et al., Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti-Epidermal Growth Factor Receptor Antibody Therapies, Cancer Research, vol.67, issue.6, pp.2643-2648, 2007.
DOI : 10.1158/0008-5472.CAN-06-4158

K. Sakata, S. Kato, J. Fox, M. Shigemori, and M. Morimatsu, Autocrine Signaling through Ras Regulates Cell Survival Activity in Human Glioma Cells: Potential Cross-Talk between Ras and the Phosphatidylinositol 3-Kinase-Akt Pathway, Journal of Neuropathology & Experimental Neurology, vol.61, issue.11, pp.975-983, 2002.
DOI : 10.1093/jnen/61.11.975

M. Jhawer, S. Goel, A. Wilson, C. Montagna, Y. Ling et al., PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab, Cancer Research, vol.68, issue.6, pp.1953-1961, 2008.
DOI : 10.1158/0008-5472.CAN-07-5659

F. Loupakis, L. Pollina, I. Stasi, A. Ruzzo, M. Scartozzi et al., PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.16, pp.2622-2629, 2009.
DOI : 10.1200/JCO.2008.20.2796

M. Moroni, S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore-bianchi et al., Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study, The Lancet Oncology, vol.6, issue.5, pp.279-286, 2005.
DOI : 10.1016/S1470-2045(05)70102-9

A. Sartore-bianchi, M. Moroni, S. Veronese, C. Carnaghi, E. Bajetta et al., Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab, Journal of Clinical Oncology, vol.25, issue.22, pp.3238-3245, 2007.
DOI : 10.1200/JCO.2007.11.5956

B. Gumuskaya, M. Alper, S. Hucumenoglu, K. Altundag, A. Uner et al., EGFR expression and gene copy number in triple-negative breast carcinoma, Cancer Genetics and Cytogenetics, vol.203, issue.2, pp.222-229, 2010.
DOI : 10.1016/j.cancergencyto.2010.07.118

V. Secq, J. Villeret, F. Fina, M. Carmassi, X. Carcopino et al., Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations, British Journal of Cancer, vol.486, issue.4, pp.1045-1052, 2014.
DOI : 10.1016/j.clinbiochem.2008.09.099

URL : http://www.nature.com/bjc/journal/v110/n4/pdf/bjc2013794a.pdf

P. Lamy, F. Fina, C. Bascoul-mollevi, A. Laberenne, P. Martin et al., Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers, Breast Cancer Research, vol.100, issue.15 Suppl, p.15, 2011.
DOI : 10.1093/jnci/djm252

F. Elstrodt, A. Hollestelle, J. Nagel, M. Gorin, M. Wasielewski et al., Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants, Cancer Research, vol.66, issue.1, pp.41-45, 2006.
DOI : 10.1158/0008-5472.CAN-05-2853

J. Baselga, D. Rischin, M. Ranson, H. Calvert, R. E. Kieback et al., Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types, Journal of Clinical Oncology, vol.20, issue.21, pp.4292-4302, 2002.
DOI : 10.1200/JCO.2002.03.100

J. Mccubrey, L. Steelman, W. Chappell, S. Abrams, E. Wong et al., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1773, issue.8, pp.1263-1284, 2007.
DOI : 10.1016/j.bbamcr.2006.10.001

S. Meloche and J. Pouyssegur, The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition, Oncogene, vol.12, issue.22, pp.3227-3239, 2007.
DOI : 10.1074/jbc.272.47.29967

URL : https://hal.archives-ouvertes.fr/hal-00319874

J. Davis, P. Navolanic, C. Weinstein-oppenheimer, L. Steelman, W. Hu et al., Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance, Clin Cancer Res, vol.9, pp.1161-1170, 2003.

Y. Yi, W. Hong, H. Kang, H. Kim, W. Zhao et al., Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells, Journal of Cellular and Molecular Medicine, vol.30, issue.5, pp.648-656, 2013.
DOI : 10.1200/JCO.2011.38.2010

F. Yamasaki, D. Zhang, C. Bartholomeusz, T. Sudo, G. Hortobagyi et al., Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity, Molecular Cancer Therapeutics, vol.6, issue.8, pp.2168-2177, 2007.
DOI : 10.1158/1535-7163.MCT-06-0514

E. D. Gennaro, M. Barbarino, F. Bruzzese, D. Lorenzo, S. Caraglia et al., Critical role of both p27KIP1and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (?Iressa?), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells, Journal of Cellular Physiology, vol.61, issue.1, pp.139-150, 2003.
DOI : 10.1002/jcp.10239

R. Weinberg, The retinoblastoma protein and cell cycle control, Cell, vol.81, issue.3, pp.323-330, 1995.
DOI : 10.1016/0092-8674(95)90385-2

URL : https://doi.org/10.1016/0092-8674(95)90385-2

Y. Ma, L. Chen, G. Wright, S. Pillai, S. Chellappan et al., CDKN1C Negatively Regulates RNA Polymerase II C-terminal Domain Phosphorylation in an E2F1-dependent Manner, Journal of Biological Chemistry, vol.17, issue.13, pp.9813-9822, 2010.
DOI : 10.3945/jn.109.110320

M. Suenaga, A. Yamaguchi, H. Soda, K. Orihara, Y. Tokito et al., Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity, Anticancer Res, vol.26, pp.3387-3391, 2006.

D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg et al., Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer, New England Journal of Medicine, vol.351, issue.4, pp.337-345, 2004.
DOI : 10.1056/NEJMoa033025

URL : http://www.nejm.org/doi/pdf/10.1056/NEJMoa033025

R. Giusti, K. Shastri, A. Pilaro, C. Fuchs, R. Cordoba-rodriguez et al., U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens, Clinical Cancer Research, vol.14, issue.5, pp.1296-1302, 2008.
DOI : 10.1158/1078-0432.CCR-07-1354

A. Sanchez-munoz, E. Gallego, V. De-luque, L. Perez-rivas, L. Vicioso et al., Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer, BMC Cancer, vol.13, issue.2 Pt 1, p.136, 2010.
DOI : 10.1158/1078-0432.CCR-06-0267

A. Karnoub and R. Weinberg, Ras oncogenes: split personalities, Nature Reviews Molecular Cell Biology, vol.21, issue.7, pp.517-531, 2008.
DOI : 10.1172/JCI200418829

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915522/pdf

E. Tilch, T. Seidens, S. Cocciardi, L. Reid, D. Byrne et al., Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women, Breast Cancer Research and Treatment, vol.14, issue.2, pp.385-392, 2014.
DOI : 10.1186/bcr3150

S. Shah, A. Roth, R. Goya, A. Oloumi, G. Ha et al., The clonal and mutational evolution spectrum of primary triple-negative breast cancers, Nature, vol.464, pp.395-399, 2012.
DOI : 10.1038/nature08989

E. Cerami, J. Gao, U. Dogrusoz, B. Gross, S. Sumer et al., The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1., Cancer Discovery, vol.2, issue.5, pp.401-404, 2012.
DOI : 10.1158/2159-8290.CD-12-0095

B. Lehmann, J. Bauer, X. Chen, M. Sanders, A. Chakravarthy et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, Journal of Clinical Investigation, vol.121, issue.7, pp.2750-2767, 2011.
DOI : 10.1172/JCI45014DS1

P. Kenny, G. Lee, C. Myers, R. Neve, J. Semeiks et al., The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression, Molecular Oncology, vol.66, issue.1, pp.84-96, 2007.
DOI : 10.1158/0008-5472.CAN-05-4081

R. Neve, K. Chin, J. Fridlyand, J. Yeh, F. Baehner et al., A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes, Cancer Cell, vol.10, issue.6, pp.515-527, 2006.
DOI : 10.1016/j.ccr.2006.10.008

G. Tomlinson, T. Chen, V. Stastny, A. Virmani, M. Spillman et al., Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier, Cancer Res, vol.58, pp.3237-3242, 1998.

V. Vichai and K. Kirtikara, Sulforhodamine B colorimetric assay for cytotoxicity screening, Nature Protocols, vol.129, issue.3, pp.1112-1116, 2006.
DOI : 10.1038/nprot.2006.179

M. Privat, C. Aubel, S. Arnould, Y. Communal, M. Ferrara et al., Breast cancer cell response to genistein is conditioned by BRCA1 mutations, Biochemical and Biophysical Research Communications, vol.379, issue.3, pp.785-789, 2009.
DOI : 10.1016/j.bbrc.2008.12.151

T. Chou, Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, Pharmacological Reviews, vol.58, issue.3, pp.621-681, 2006.
DOI : 10.1124/pr.58.3.10

K. Livak and T. Schmittgen, Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2???????CT Method, Methods, vol.25, issue.4, pp.402-408, 2001.
DOI : 10.1006/meth.2001.1262

F. Kwiatkowski, M. Girard, K. Hacene, and J. Berlie, Sem: a suitable statistical software adaptated for research in oncology], Bull Cancer, vol.87, pp.715-721, 2000.